Advice on physical activity should be encouraged as part of treatment for adults with depressive episode/disorder with inactive lifestyles. In moderate and severe depression, this intervention should be considered as adjunct to antidepressants or brief structured psychological treatments.
Snakebite is an acute life threatening time limiting medical emergency. It is a preventable public
health hazard often faced by rural population in tropical and subtropical countries with heavy
rainfall and humid climate.
Les directives 2021 de l’European Resuscitation Council (ERC - Conseil Européen de Réanimation) sont fondées sur une série de revues systématiques, sur la revue du champ d'application, et sur les mises à jour des évidences de sciences de l’ILCOR (International Liaison Commitee on Resuscit...ation). Elles présentent les directives les plus récentes, basées sur des données probantes, pour la pratique de la réanimation en Europe. Ces directives portent sur l’épidémiologie de l’arrêt cardiaque, le rôle que jouent les systèmes de secours pour sauver des vies, la réanimation chez l’adulte, tant en réanimation de base, qu'en réanimation avancée, la réanimation dans des circonstances spéciales, les soins postréanimation, les premiers secours, la réanimation néonatale et pédiatrique, l'éthique et l'enseignement.
more
Q4: In individuals with long term and/or recurrent psychotic disorders (including schizophrenia), should individuals be maintained on pharmacotherapy indefinitely or withdrawn from treatment in order to allow for the best outcomes?
N Engl J Med 2022; 386:911-922, DOI: 10.1056/NEJMoa2104535
Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis (SHINE Study)
Die aktuellen Leitlinien stellen detailliert und umfassend die gesamte wissen-
schaftliche Basis und die daraus abgeleiteten Therapieempfehlungen in elf Einzel-
kapiteln dar. Darunter befinden sich auch allgemeingültige Empfehlungen wie
zum Beispiel zur Ausbildung und zu ethischen Fragestellunge...n am Lebensende.
Um Ihnen einen möglichst schnellen und gleichzeitig umfassenden Überblick zu
ermöglichen, haben wir für Sie in diesem Taschenbuch die wesentlichen Aussagen
aus allen Kapiteln als Kurzfassung zusammengestellt.
more
La presente publicación describe un resumen de la evidencia científica disponible sobre el uso de Cloroquina e hidroxicloroquina, así como su profilaxis y tratamiento para COVID-19.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19
La presente publicación describe la evidencia científica disponible sobre la efectividad del uso de mascarillas o respiradores en la prevención y control de infecciones respiratorias virales incluido COVID-19 a nivel comunitario y hospitalario. Se identificaron 778 estudios publicados hasta abril... de 2020 como parte de la búsqueda sistemática de evidencias (320 población general y 452 personal de salud). Siete estudios fueron seleccionados para responder a las preguntas de investigación de los cuales cinco fueron ensayos clínicos respecto al subgrupo de población general y una revisión sistemática y un ensayo clínico respecto al subgrupo de personal de salud.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19
more
La presente publicación describe la evidencia científica disponible sobre la precisión diagnóstica de las pruebas rápidas de detección de antígenos para SARS-COV-2. El conocimiento de las pruebas diagnósticas para el coronavirus del síndrome respiratorio agudo grave 2 (SARS-COV-2) sigue evo...lucionando, y una comprensión clara de la naturaleza de las pruebas y la interpretación de sus hallazgos es importante. Este punto de vista describe cómo interpretar 2 tipos de pruebas diagnósticas comúnmente en uso para las infecciones SARS-COV-2: reacción en cadena de polimerasa con transcriptasa reversa (RT-PCR) y ensayo por inmunoabsorción ligado a enzimas IgM e IgG (ELISA)— y cómo los resultados pueden variar con el tiempo.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19
more
“Guide to facilitate the implementation of the WHO/UNICEF “Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines” for Africa
t contains action-oriented lists of critical topics to address and checklists tailored to the context of African Union Member States.
...
The contents of this guide aim to guide the development of one comprehensive national deployment and vaccination plan, as proposed and outlined by the guidance – and underlines the need for countries to develop their vaccination plans.
This guide is not meant as a tool to assess deployment readiness. The recommendation to Member States is to use the VIRAT/VRAF 2.0 tool for that, which builds on the COVAX Vaccine Introduction Readiness Assessment Tool (VIRAT) and the World Bank’s Vaccine Readiness Assessment Framework (VRAF).
more
Slideset updated regularly to include the latest data and guidance on COVID-19 risk and management in special populations, including children and pregnant women, and persons with comorbidities.
26 March 2021 Slideset updated regularly to include the latest data on the evolution and duration of COVID-19 symptoms and prevalence and duration of natural immunity.
SBMFC Recommendations for PHC during the Pandemic of COVID-19 (edition 4)
This document answers questions and gives recommendations so that the Brazilian PHC can quickly receive the best possible scientific synthesis on the current situation of the pandemic of COVID-19
Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States.
Currently..., there is:
1. No scientific evidence from pre-clinical studies on the therapeutic effect of ivermectin for the management of COVID-19;
2. No evidence of its clinical efficacy for the management of patients with asymptomatic, mild, moderate or severe COVID-19; and
3. No safety data regarding the use of ivermectin for COVID-19 in the majority of the published studies.
more
How far apart should the doses of vaccines be? What if I miss my second dose? Can I get two doses from two different manufacturers? How was safety of vaccines ensured? WHO’s Chief Scientist, Dr Soumya Swaminathan explains in Science in 5.
Änderung gegenüber der Version vom 26.1.2021: Aktualisierung der Informationen über monoklonale Antikörper und Rekonvaleszentenplasma